A Phase 4 interventional study of Insulin Lispro-aabc and Insulin Glargine in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 12 sites in India. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 16th largest by enrollment, is the only one that started in 2024, is one of 15 in phase 4, and was the 36th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →
Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 153 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 127 across the 36 interventional studies. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 36 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 542 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 20 under way, 11 of them phase 3. Of 212 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 123rd largest by enrollment of the 232 interventional ones that give a count, is one of 9 that started in 2024, is one of 33 in phase 4, and was the 212th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the safety of insulin lispro-aabc in adult participants with Type 2 diabetes mellitus in India.
The study will last about 33 weeks for each participant, including screening (1 week), Lead-in period (4 weeks), treatment period (26 weeks) and follow up period (2 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Treated for ≥90 days prior to screening with multiple daily injection (MDI) therapy
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received subcutaneous injections of insulin lispro-aabc 100 units/millilitre (U/mL) immediately (0 to 2 minutes) before each meal, in combination with once-daily insulin glargine 100 U/mL as basal insulin, during the 26-week treatment period.
Drug: Insulin Lispro-aabc · Drug: Insulin Glargine
Administered subcutaneously
Also known as: LY900014, Lyumjev
Administered subcutaneously
Also known as: Basaglar
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL)
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.
Time frame: Baseline through Week 26
Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
Time frame: Baseline through Week 26
Percentage of Participants With Severe Hypoglycemia
* Severe hypoglycemia is considered any hypoglycemic event where the participant requires assistance for recovery with or without hospitalisation and is reported as a serious adverse event. * The percentage of participants with at least 1 severe hypoglycemic event was calculated as the number of participants with \>=1 severe hypoglycemic event divided by the total number of participants, multiplied by 100.
Time frame: Baseline through Week 26
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.
Time frame: Baseline through Week 26
Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
Time frame: Baseline through Week 26
Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.
Time frame: Baseline through Week 26
Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
Time frame: Baseline through Week 26
Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.
Time frame: Baseline through Week 26
Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
Time frame: Baseline through Week 26
Change From Baseline in Body Weight
Time frame: Baseline, Week 26
Change From Baseline in Hemoglobin A1c (HbA1c)
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Baseline, Week 26
Percentage of Participants Achieving HbA1c < 7%
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
Time frame: Week 26
Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score
The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin under 5 domains: Inconvenience of Regimen \[5 items\], Lifestyle Flexibility \[3 items\], Glycemic Control \[3 items\], Hypoglycemic Control \[5 items\], Insulin Delivery Device \[6 items\]. Each Item is measured on a 7-point scale. The overall score is calculated as the mean of all 22 items and transformed to a scale of 0 to 100 using the formula: 100\*\[(7 - raw overall score)/6\], with higher scores indicating better treatment satisfaction.
Time frame: Baseline, Week 26
Change From Baseline in 1- and 2-hour Postprandial Glucose (PPG) Values Estimated From Self-monitored Blood Glucose (SMBG) Values
Time frame: Baseline, Day 3 of Week 20
Change From Baseline in Bolus Insulin Dose, Basal Insulin Dose
* Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days.
Time frame: Baseline, Week 20
Change From Baseline in Basal to Bolus Insulin Dose Ratio
Basal to Bolus insulin dose ratio, calculated as the basal insulin dose divided by the basal insulin dose. * Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days
Time frame: Baseline, Week 20
Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values
SMBG measurements were taken at 9 time points: fasting, 1 hour post-breakfast, 2 hours post-breakfast, pre-lunch, 1 hour post-lunch, 2 hours post-lunch, pre-dinner, 1 hour post-dinner, and 2 hours post-dinner. The SMBG value was calculated as the average of the corresponding SMBG measurements collected on Days 1, 2, and 3 across cumulative non-missing data days.
Time frame: Baseline, Week 20
| Milestone | Insulin Lispro-aabc |
|---|---|
| Started | 153 |
| Received at least one dose of insulin lispro-aabc | 150 |
| Completed | 144 |
| Not completed | 9 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Adverse event | 2 |
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.
| percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <54 Milligrams Per Deciliter (mg/dL) | 4 |
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
| events/participant/year | Insulin Lispro-aabc |
|---|---|
| Rate of Documented Hypoglycemia With Blood Glucose <54 mg/dL | 0.08 |
* Severe hypoglycemia is considered any hypoglycemic event where the participant requires assistance for recovery with or without hospitalisation and is reported as a serious adverse event. * The percentage of participants with at least 1 severe hypoglycemic event was calculated as the number of participants with \>=1 severe hypoglycemic event divided by the total number of participants, multiplied by 100.
| Percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants With Severe Hypoglycemia | 0 |
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.
| percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <54 mg/dL | 0.7 |
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
| events/participant/year | Insulin Lispro-aabc |
|---|---|
| Rate of Nocturnal Hypoglycemia With Blood Glucose <54 mg/dL | 0.01 |
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * The percentage of participants with at least 1 nocturnal hypoglycemic event was calculated as the number of participants with \>=1 nocturnal hypoglycemic event divided by the total number of participants, multiplied by 100.
| percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants With at Least 1 Nocturnal Hypoglycemic Event With Blood Glucose <70 mg/dL | 4 |
* Nocturnal hypoglycemia is considered any hypoglycemic event (documented hypoglycemia or probable symptomatic hypoglycemia, including severe hypoglycemia) that occurs between bedtime and waking (11:59 PM to 5:59 AM). * Rate of nocturnal hypoglycemia (events/participant/year) was calculated as the sum of nocturnal hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
| events/participant/year | Insulin Lispro-aabc |
|---|---|
| Rate of Nocturnal Hypoglycemia With Blood Glucose <70 mg/dL | 0.08 |
The percentage of participants with at least 1 documented hypoglycemic event was calculated as the number of participants with \>=1 documented hypoglycemic event divided by the total number of participants, multiplied by 100.
| percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants With at Least 1 Documented Hypoglycemic Event With Blood Glucose <70 mg/dL | 22 |
Rate of documented hypoglycemia (events/participant/year) was calculated as the sum of documented hypoglycemic episodes divided by the cumulative days on treatment from all participants, multiplied by 365.
| events/participant/year | Insulin Lispro-aabc |
|---|---|
| Rate of Documented Hypoglycemia With Blood Glucose <70 mg/dL | 0.77 |
| kilogram (kg) | Insulin Lispro-aabc |
|---|---|
| Change From Baseline in Body Weight | 0.3 ± 0.18 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
| percentage of HbA1c | Insulin Lispro-aabc |
|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) | -0.8 ± 0.11 |
HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time.
| percentage of participants | Insulin Lispro-aabc |
|---|---|
| Percentage of Participants Achieving HbA1c < 7% | 21.6 |
The ITSQ is a 22-item questionnaire that assesses treatment satisfaction for participants taking insulin under 5 domains: Inconvenience of Regimen \[5 items\], Lifestyle Flexibility \[3 items\], Glycemic Control \[3 items\], Hypoglycemic Control \[5 items\], Insulin Delivery Device \[6 items\]. Each Item is measured on a 7-point scale. The overall score is calculated as the mean of all 22 items and transformed to a scale of 0 to 100 using the formula: 100\*\[(7 - raw overall score)/6\], with higher scores indicating better treatment satisfaction.
| score on a scale | Insulin Lispro-aabc |
|---|---|
| Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ) Score | 5.7 ± 0.86 |
| mg/dL | Insulin Lispro-aabc |
|---|---|
| 1-hour Postprandial | -19.2 ± 3.29 |
| 2-hour Postprandial | -22.2 ± 3.29 |
* Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days.
| Units/day | Insulin Lispro-aabc |
|---|---|
| Bolus Insulin Dose | 3.5 ± 0.72 |
| Basal insulin Dose | 2.6 ± 0.52 |
Basal to Bolus insulin dose ratio, calculated as the basal insulin dose divided by the basal insulin dose. * Bolus insulin dose, calculated as the summed daily bolus insulin dose across days 1, 2 and 3 divided by the number of non-missing data days. * Basal insulin dose, calculated as the summed daily basal insulin dose across days 1, 2 and 3 divided by the number of non-missing data days
| ratio | Insulin Lispro-aabc |
|---|---|
| Change From Baseline in Basal to Bolus Insulin Dose Ratio | 0.0 ± 0.02 |
SMBG measurements were taken at 9 time points: fasting, 1 hour post-breakfast, 2 hours post-breakfast, pre-lunch, 1 hour post-lunch, 2 hours post-lunch, pre-dinner, 1 hour post-dinner, and 2 hours post-dinner. The SMBG value was calculated as the average of the corresponding SMBG measurements collected on Days 1, 2, and 3 across cumulative non-missing data days.
| mg/dL | Insulin Lispro-aabc |
|---|---|
| Change From Baseline in 9-Point Self-Monitored Blood Glucose (SMBG) Values | -18.0 ± 40.57 |
Collected over Baseline to end of safety follow-up (up to 42 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Lispro-aabc | 0/150 (0%) | 4/150 (2.7%) | 49/150 (32.7%) |
| Event | Insulin Lispro-aabc |
|---|---|
| Angina unstableCardiac disorders | 1/150 |
| CataractEye disorders | 1/150 |
| GastritisGastrointestinal disorders | 1/150 |
| Radius fractureInjury, poisoning and procedural complications | 1/150 |
| HyperglycaemiaMetabolism and nutrition disorders | 1/150 |
| Event | Insulin Lispro-aabc |
|---|---|
| PyrexiaGeneral disorders | 6/150 |
| Abdominal distensionGastrointestinal disorders | 5/150 |
| Injection site painGeneral disorders | 5/150 |
| Injection site erythemaGeneral disorders | 4/150 |
| ObesityMetabolism and nutrition disorders | 3/150 |
| Burning sensationNervous system disorders | 3/150 |
| HeadacheNervous system disorders | 3/150 |
| NasopharyngitisInfections and infestations | 2/150 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/150 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/150 |
All participants who received at least one dose of insulin lispro-aabc.
| Age, Continuous(years) | Insulin Lispro-aabc |
|---|---|
| Mean | 56.6 ± 12.05 |
| Sex: Female, Male(Participants) | Insulin Lispro-aabc |
|---|---|
| Female | 65 |
| Male | 85 |
| Race (NIH/OMB)(Participants) | Insulin Lispro-aabc |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 150 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Insulin Lispro-aabc |
|---|---|
| India | 150 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Apr 2024 to primary completion in Sep 2025, 16 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 16 months is below that.
Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Lispro